Meeder Asset Management Inc Arcutis Biotherapeutics, Inc. Transaction History

Meeder Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$17.85 - $26.95 $18,421 - $27,812	1,032 New	1,032 $20,000
Q4 2021 Feb 11, 2022	SELL	$14.98 - $25.5 $40,191 - $68,416	-2,683 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$19.28 - $27.1 $7,827 - $11,002	406 Added 17.83%	2,683 $64,000
Q2 2021 Aug 09, 2021	BUY	$24.42 - $34.75 $22,075 - $31,414	904 Added 65.84%	2,277 $62,000
Q1 2021 Apr 28, 2021	BUY	$24.47 - $36.98 $33,597 - $50,773	1,373 New	1,373 $40,000
Q4 2020 Feb 09, 2021	SELL	$17.82 - $31.73 $7,181 - $12,787	-403 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$23.44 - $32.28 $9,446 - $13,008	403 New	403 $11,000
Q2 2020 Aug 11, 2020	SELL	$24.48 - $36.56 $342 - $511	-14 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$18.5 - $36.9 $259 - $516	14 New	14 $0

197

129M

738K

82K

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $557M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.